Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma

被引:145
作者
Lee, Won-Suk [1 ]
Lee, Kwang-Woong [1 ]
Heo, Jin-Seok [1 ]
Kim, Sung-Ju [1 ]
Choi, Seong-Ho [1 ]
Kim, Yong-Il [1 ]
Joh, Jae-Won [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, Seoul 135710, South Korea
关键词
combined type hepatocelluar carcinoma; hepatocelluar carcinoma; intrahepatic cholangiocarcinoma; hepatic resection; cholangiocarcinoma;
D O I
10.1007/s00595-006-3276-8
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose. Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation. We compared the outcome of hepatic resection in patients with HCC-CC, those with hepatocelluar carcinoma (HCC), and those with cholangiocarcinoma (ICC). Methods. Between November 1994 and December 2003, 952 patients underwent hepatic resection for a PHN. Results. The incidence of HCC-CC was 3.5%. Hepatitis B surface antigen was positive in 51.2% of these patients and the HCV antibody was positive in 12.2%. Positive hepatitis serology was more common in the HCC group (66.7%). The prevalence of underlying liver cirrhosis was significantly lower in the ICC group (7.8%) than in the HCC (49%) and HCC-CC (41.5%) groups (P < 0.0001). The median overall survival periods after hepatic resection of HCC-CC, HCC, and ICC were 47.3, 71.7, and 21.5 months, respectively (P < 0.0001). The median disease-free survival (DFS) periods after hepatic resection for HCC-CC, HCC, and ICC were 23.4, 68.2, and 15.5 months, respectively (P < 0.0001). Conclusion. Patients with transitional type HCC-CC had significantly poorer survival rates than those with HCC, after hepatic resection. Therefore, a more aggressive treatment modality should be explored to improve the survival rate of these patients.
引用
收藏
页码:892 / 897
页数:6
相关论文
共 16 条
[1]  
ALLEN RA, 1949, AM J PATHOL, V25, P647
[2]  
EDMONDSON HA, 1958, ATLAS TUMOR PATHOL, P32
[3]  
GOODMAN ZD, 1985, CANCER-AM CANCER SOC, V55, P124, DOI 10.1002/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO
[4]  
2-Z
[5]  
ISHAK K, 1994, HISTOLOGICAL TYPING
[6]   Combined hepatocellular and cholangiocarcinoma - Demographic, clinical, and prognostic factors [J].
Jarnagin, WR ;
Weber, S ;
Tickoo, SK ;
Koea, JB ;
Obiekwe, S ;
Fong, YM ;
DeMatteo, RP ;
Blumgart, LH ;
Klimstra, D .
CANCER, 2002, 94 (07) :2040-2046
[7]   Hepatic resection for combined hepatocellular and cholangiocarcinoma [J].
Liu, CL ;
Fan, ST ;
Lo, CM ;
Ng, IOL ;
Lam, CM ;
Poon, RTP ;
Wong, J .
ARCHIVES OF SURGERY, 2003, 138 (01) :86-90
[8]  
Liver Cancer Study Group of Japan, 1997, CLASS PRIM LIV CANC
[9]   COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA - PROPOSED CRITERIA ACCORDING TO CYTOKERATIN EXPRESSION AND ANALYSIS OF CLINICOPATHOLOGICAL FEATURES [J].
MAEDA, T ;
ADACHI, E ;
KAJIYAMA, K ;
SUGIMACHI, K ;
TSUNEYOSHI, M .
HUMAN PATHOLOGY, 1995, 26 (09) :956-964
[10]   Combined hepatocellular-cholangiocarcinoma: A clinicopathological study [J].
Ng, IOL ;
Shek, TWH ;
Nicholls, J ;
Ma, LT .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (01) :34-40